SiBone (NASDAQ:SIBN) Stock: Insider Laura Francis Sells 38,006 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 38,006 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $20.05, for a total value of $762,020.30. Following the completion of the sale, the chief executive officer owned 379,256 shares of the company’s stock, valued at $7,604,082.80. This represents a 9.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total value of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Price Performance

SiBone stock opened at $19.91 on Friday. The firm has a market capitalization of $883.01 million, a P/E ratio of -58.56 and a beta of 0.66. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The business has a 50-day moving average of $18.95 and a 200-day moving average of $16.53. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. On average, equities analysts anticipate that SiBone will post -0.40 EPS for the current year.

Institutional Investors Weigh In On SiBone

A number of hedge funds have recently modified their holdings of SIBN. First Light Asset Management LLC lifted its holdings in shares of SiBone by 51.8% during the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC raised its holdings in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after buying an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY raised its holdings in SiBone by 113.3% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after buying an additional 598,300 shares during the period. Dimensional Fund Advisors LP raised its holdings in SiBone by 41.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after buying an additional 182,465 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after buying an additional 238,219 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Truist Financial lifted their price target on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen lifted their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, UBS Group boosted their price target on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.

About SiBone

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.